William Arnold, MD
Neuromuscular Medicine · Columbia, MONPI 1174653976
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,840 of the $41,831 with a category attached, or 80.9%. Genentech, Inc. accounts for 91.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $29,460 and has fallen 92.3% since, to $2,274 in 2025.
Across 28 payments — averaging $1493.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$38K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1K
- Sarepta Therapeutics, Inc.$50
- Insmed, Inc.$19
Across 9 payments — averaging $5424.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$31K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Novartis$5K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$33,84081%
- Speaking & faculty fees$3,8649%
- Travel & lodging$3,0377%
- Food & beverage$8622%
- Education$2271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 12 | $38,415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $2,255 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $1,092 |
| Sarepta Therapeutics, Inc. | 1 | $50 |
| Insmed, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$32,310
- ZOLGENSMA$1,092
How this compares
Too few neuromuscular medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 22 | $326,765 |
| Riluzole | 19 | $2,323 |
| Ranolazine ErRanolazine | 15 | $878 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Columbia
- Richard BarohnColumbia$11K
- Ryan CastoroColumbia$7K
- Erik EnsrudColumbia$5K
- Karim SalameColumbia$4K
- Nesreen JaafarColumbia$255
- Melanie GlennColumbia$90
- Niranjan SinghSaint Louis$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.